Likelihood of Approval and Phase Transition Success Rate Model – Bifikafusp Alfa + Onfekafusp Alfa in Metastatic Melanoma
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Bifikafusp Alfa + Onfekafusp Alfa in Metastatic Melanoma report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Bifikafusp Alfa + Onfekafusp Alfa in Metastatic Melanoma Drug Details:
Daromun (L19-IL2 + L19-TNF) is under development for the treatment of metastatic melanoma, non-melanomatous skin cancer including basal cell carcinoma (basal cell epithelioma), squamous cell carcinoma, stage III and IV unresectable melanoma patients, cutaneous squamous cell carcinoma (cSCC), Merkel cell carcinoma, keratoacanthoma, tumoral cutaneous T-cell lymphoma, Kaposi’s sarcoma or Adnexal tumors of the Skin and other types of skin cancer. The drug candidate is administered intratumorally and intralesional. L19-IL2 and L19-TNF are recombinant fusion proteins, composed of the single-chain monoclonal antibody fragment (L19). L19-IL2 is composed of human recombinant interleukin-2 (IL-2). L19-TNF is composed of human recombinant tumor necrosis factor-alpha. The drug candidate acts by targeting fibronectin and interleukin 2 receptor subunit alpha (IL2RA).
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Bifikafusp Alfa + Onfekafusp Alfa LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports